Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
26, 2015, pp
90% of participants were male, and 80% were white
Two open-label trials in PsA patients with obesity indicated improvements in disease activity (MDA) alongside metabolic benefits
The authors concluded: Further research is needed to determine if there is a true cause and effect relationship in the association identified in this investigation and to understand the trade-offs between the benefits and risks of GLP-1 RAs. Also in June, the European Medicines Agency safety committee warned that semaglutide (active substance in Ozempic, Rybelsus and Wegovy) may cause the NAION optic neuropathy described earlier in this article
Treatment decisions should be made in consultation with a licensed medical professional who can evaluate individual health factors, contraindications, and clinical eligibility
Clinical data shows that some GLP-1 agonists may actually provide modest cardiovascular benefits, though blood pressure monitoring remains essential during treatment initiation and adjustment
